title: Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?
authors.affiliation: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
authors.affiliation: Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts2Associate Editor, JAMA.
authors.forename: Deborah
authors.initials: D
authors.lastname: Schrag
mesh_terms: D059451:Biosimilar Pharmaceuticals; D001943:Breast Neoplasms; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D059451:Biosimilar Pharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases